Sign In
NASDAQ:CALA
Calithera Biosciences Stock News
$0.0006
+0 (+0%)
At Close: Mar 17, 2025
Calithera Biosciences, Inc. (CALA) Q3 2022 Earnings Call Transcript
10:17pm, Monday, 14'th Nov 2022
Calithera Biosciences, Inc. (NASDAQ:CALA ) Q3 2022 Earnings Conference Call November 14, 2022 5:00 PM ET Company Participants Stephanie Wong - CFO & Secretary Susan Molineaux - Founder, CEO, President
Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
09:30pm, Tuesday, 08'th Nov 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company’s
Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
04:30pm, Tuesday, 08'th Nov 2022
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company's thi
KalVista (KALV) Stock Continues to Decline: Here's Why
05:50pm, Thursday, 06'th Oct 2022 Zacks Investment Research
The recent setback faced by KalVista (KALV) for terminating the phase II KOMPLETE study evaluating KVD824 for prophylactic treatment of hereditary angioedema hurts the stock.
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
07:24am, Tuesday, 04'th Oct 2022 Benzinga
Gainers
LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per
Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday's Mid-Day Session
04:27pm, Monday, 03'rd Oct 2022 Benzinga
Gainers
LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.
FedNat Holding Com
Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer
11:00am, Monday, 03'rd Oct 2022 GlobeNewswire Inc.
Enrollment ongoing in Phase 2 study evaluating sapanisertib, a dual mTORC1/2 inhibitor, in patients with squamous non-small cell lung cancer harboring a NRF2 mutation Enrollment ongoing in Phase 2 stu
Calithera's stock is up 14% after announcing Fast Track designation for lung-cancer drug candidate
09:08am, Monday, 03'rd Oct 2022
Shares of Calithera Biosciences Inc. CALA, -0.68% jumped 14.6% in premarket trading on Monday after the company said it received a Fast Track designation for its experimental treatment for non-small c
Spectrum (SPPI) Down as FDA Panel Votes Against NSCLC Drug
04:09pm, Monday, 26'th Sep 2022 Zacks Investment Research
The FDA Oncologic Drugs Advisory Committee votes against Spectrum's (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations. Stock down.
Pacira's (PCRX) Label Expansion Study on Exparel Meets Goal
02:23pm, Thursday, 22'nd Sep 2022 Zacks Investment Research
Pacira's (PCRX) phase III study evaluating its marketed drug, Exparel, as a single-dose sciatic nerve block in the popliteal fossa for bunionectomy meets primary and secondary endpoints.
3 Penny Stocks With Surprisingly Superior Fundamentals
03:14pm, Friday, 09'th Sep 2022
The question of when to add risk to a portfolio is a difficult one to answer. A rush toward riskier equities after the pandemic-induced sell-off led to a surge in many stocks.
Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference
08:05pm, Tuesday, 06'th Sep 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan
Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference
04:05pm, Tuesday, 06'th Sep 2022
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan M
Why Bed Bath & Beyond Jumped Around 25%; Here Are 68 Biggest Movers From Yesterday
09:23am, Tuesday, 30'th Aug 2022 Benzinga
Gainers
American Virtual Cloud Technologies, Inc. (NASDAQ: AVCT) climbed 156.3% to close at $0.3750 on Monday. American Virtual Cloud Technologies shares gained around 8% on Friday after the company
This Small Cap Cancer Stock Gets An Upgrade And Price Target Bump On 'Clinical Programs Progress'
07:52pm, Monday, 29'th Aug 2022 Benzinga
HC Wainwright updated its model on Calithera Biosciences Inc (NASDAQ: CALA), reflecting the recent Q2 earnings with no revenues and a net loss of $1.69 per share for 2022.
The analyst upgraded
